Published in Gene Therapy Weekly, April 3rd, 2003
According to a study from the United States, "in order to target recombinant adenovirus (AdV), we have developed a new strategy using a fusion ligand protein comprising coxsackievirus/adenovirus receptor (CAR), and the antibody Fc-binding domain from protein A in in vitro testing with this ligand shows that it blocks viral gene transduction and, when coupled with anti-ICAM-1 1gG, redirects AdV to endothelial cells that are induced to express ICAM-1."
"Because the protein A Fc-binding domain will bind to any immunoglobulin, the current strategy can be adapted to target a wide variety of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.